Osteoporosis in chronic obstructive pulmonary disease patients

被引:64
作者
Jorgensen, Niklas Rye [1 ,2 ]
Schwarz, Peter [2 ]
机构
[1] Roskilde Univ Hosp, Dept Clin Biochem, DK-4000 Roskilde, Denmark
[2] Copenhagen Univ Hosp, Dept Rheumatol & Geriatr, Res Ctr Ageing & Osteoporosis, Glostrup, Denmark
关键词
bone loss; chronic obstructive pulmonary disease; glucocorticoids; osteoporosis;
D O I
10.1097/MCP.0b013e3282f4efb6
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review The purpose of this review is to examine the state of knowledge and clinical practice in the association of chronic obstructive pulmonary disease to osteoporosis and fracture incidence. Recent findings There is a clear association between chronic obstructive pulmonary disease and excessive bone loss/risk of fractures. Little is known about the pathophysiological processes involved in the bone loss, but recent reports point to a continuous systemic inflammatory state in patients with chronic obstructive pulmonary disease. This inflammation involves the release of inflammatory cytokines such as tumour necrosis factor-a and interleukin-1. During the course of chronic obstructive pulmonary disease, a protein catabolic process takes place, including increased production of catalytic enzymes (matrix metalloproteinases etc.), which together with the inflammatory cytokines induces bone resorption. Summary Patients with chronic obstructive pulmonary disease are at increased risk of osteoporosis and fractures. Risk factors such as smoking, advanced age, physical inactivity, malnutrition, and low weight may be responsible, but a number of pathophysiological explanations including the presence of a chronic inflammatory state with increased levels of proinflammatory cytokines and protein catalytic enzymes may also be involved. The use of oral glucocorticoids is also a significant risk factor. Increased awareness is highly warranted to diagnose osteoporosis at an early stage, and professionals should be aware of the risk of osteoporosis in this patient population.
引用
收藏
页码:122 / 127
页数:6
相关论文
共 38 条
[1]   Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications [J].
Anandarajah, AP ;
Schwarz, EM .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (02) :226-232
[2]  
[Anonymous], 2002, COCHRANE DB SYST REV
[3]   Screening for osteoporosis in postmenopausal women: Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, PS ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Mulrow, CD ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (06) :526-528
[4]   COPD and osteoporosis [J].
Biskobing, DM .
CHEST, 2002, 121 (02) :609-620
[5]  
Bolton C E, 2007, COPD, V4, P121, DOI 10.1080/15412550701341053
[6]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[7]   Enzyme catalytic activities in chronic obstructive pulmonary disease [J].
Cepelak, Ivana ;
Dodig, Slavica ;
Romic, Dominik ;
Rujancic, Nedeljka ;
Popovic-Grle, Sanja ;
Malic, Ana .
ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (05) :624-629
[8]   Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs [J].
Churg, Andrew ;
Wang, Rona ;
Wang, Xiaoshan ;
Onnervik, Per-Ola ;
Thim, Kerstin ;
Wright, Joanne L. .
THORAX, 2007, 62 (08) :706-713
[9]   Clinical use of bone densitometry - Scientific review [J].
Cummings, SR ;
Bates, D ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (15) :1889-1897
[10]   Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study [J].
de Vries, F. ;
Pouwels, S. ;
Lammers, J. W. J. ;
Leufkens, H. G. M. ;
Bracke, M. ;
Cooper, C. ;
van Staa, T. P. .
JOURNAL OF INTERNAL MEDICINE, 2007, 261 (02) :170-177